Merit Medical Systems (NASDAQ:MMSI) Issues FY 2026 Earnings Guidance

Merit Medical Systems (NASDAQ:MMSI) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 4.010-4.150 for the period, compared to the consensus estimate of 3.730. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.6 billion.

Merit Medical Systems Price Performance

Shares of Merit Medical Systems stock traded up $0.82 during mid-day trading on Tuesday, reaching $82.43. 1,038,414 shares of the stock traded hands, compared to its average volume of 732,739. The business has a 50-day moving average of $84.17 and a 200 day moving average of $85.01. Merit Medical Systems has a fifty-two week low of $77.62 and a fifty-two week high of $107.27. The company has a quick ratio of 2.86, a current ratio of 4.28 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $4.89 billion, a PE ratio of 42.27, a PEG ratio of 2.23 and a beta of 0.61.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, topping the consensus estimate of $0.96 by $0.08. The business had revenue of $393.94 million for the quarter, compared to analyst estimates of $390.77 million. Merit Medical Systems had a return on equity of 14.27% and a net margin of 8.02%.Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. On average, analysts predict that Merit Medical Systems will post 3.37 EPS for the current year.

Analyst Upgrades and Downgrades

MMSI has been the topic of several analyst reports. Piper Sandler lowered their price target on shares of Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating for the company in a report on Wednesday, February 18th. BTIG Research began coverage on shares of Merit Medical Systems in a report on Friday, February 6th. They issued a “buy” rating and a $107.00 price objective on the stock. Canaccord Genuity Group boosted their price target on Merit Medical Systems from $93.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Merit Medical Systems in a research note on Monday, December 29th. Finally, Robert W. Baird set a $108.00 target price on shares of Merit Medical Systems in a report on Tuesday, December 16th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Merit Medical Systems has a consensus rating of “Moderate Buy” and an average price target of $105.67.

Hedge Funds Weigh In On Merit Medical Systems

A number of large investors have recently added to or reduced their stakes in MMSI. Los Angeles Capital Management LLC bought a new stake in shares of Merit Medical Systems in the fourth quarter worth $25,000. Danske Bank A S acquired a new position in Merit Medical Systems during the third quarter worth $42,000. Quarry LP lifted its position in Merit Medical Systems by 185.9% in the 3rd quarter. Quarry LP now owns 526 shares of the medical instruments supplier’s stock valued at $44,000 after acquiring an additional 342 shares in the last quarter. Global Retirement Partners LLC boosted its position in shares of Merit Medical Systems by 973.6% during the fourth quarter. Global Retirement Partners LLC now owns 569 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 516 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Merit Medical Systems in the 4th quarter worth $82,000. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.